BPMUF Stock Chart & Stats
$67.15
--
Market closed
$67.15
--
Day’s Range― - ―
52-Week Range$48.35 - $79.00
Previous CloseN/A
VolumeN/A
Average Volume (3M)N/A
Market Cap
$786.95M
Enterprise Value$669.42
Total Cash (Recent Filing)$162.34M
Total Debt (Recent Filing)$89.22M
Price to Earnings (P/E)19.7
Beta0.13
Next Earnings
Aug 18, 2026EPS Estimate
4.09Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)2.65
Shares Outstanding13,425,260
10 Day Avg. VolumeN/A
30 Day Avg. VolumeN/A
Financial Highlights & Ratios
PEG Ratio-0.34
Price to Book (P/B)5.22
Price to Sales (P/S)2.88
P/FCF Ratio11.28
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)5.34
Revenue Forecast (FY)$316.17M
Bulls Say, Bears Say
Bulls Say
Cash GenerationSustained positive operating and free cash flow provides durable funding for clinical programs and commercialization without immediate equity dilution. Strong cash conversion also supports debt reduction, milestone financing and optionality for business development over the next 2–5 years.
High Margins & Revenue MomentumConsistently high gross margins and accelerating revenue reflect scalable product economics and pricing power in anti-infectives. Margin durability plus revenue growth improve internal funding capacity and underpin sustainable operating profitability if product mix remains strong.
Commercial & Balance Sheet ProgressMaterial cash build and net cash position plus successful US launch of Zevtera reduce financing risk while proving commercial execution. The stronger balance sheet and early commercial traction create durable capacity to fund Phase III programs and withstand near-term market headwinds.
Bears Say
Loss Of Exclusivity RiskCresemba LOE timing creates a structural revenue cliff risk starting in late 2027–2028. As Cresemba has been a material cash engine, generic entry will pressure royalties and cash flow, requiring successful late‑stage clinical outcomes or new launches to sustainably replace revenue.
Partner DependenceSignificant reliance on partners for commercialization and regulatory activities creates persistent execution and timing risk. Partner manufacturing transitions and differing launch capabilities can alter revenue recognition and royalties, reducing Basilea's control over key revenue streams.
Rising R&D And Timing UncertaintyMaterial near‑term R&D uplift to fund multiple Phase III programs increases burn and compresses operating leverage. Coupled with uncertain milestone timing and regulatory requirements, higher spend elevates the need for consistent nondilutive funding or sustained commercial cash flow to avoid financing risk.
Basilea Pharmaceutica News
BPMUF FAQ
What was Basilea Pharmaceutica’s price range in the past 12 months?
Basilea Pharmaceutica lowest stock price was $48.35 and its highest was $79.00 in the past 12 months.
What is Basilea Pharmaceutica’s market cap?
Basilea Pharmaceutica’s market cap is $786.95M.
When is Basilea Pharmaceutica’s upcoming earnings report date?
Basilea Pharmaceutica’s upcoming earnings report date is Aug 18, 2026 which is in 24 days.
How were Basilea Pharmaceutica’s earnings last quarter?
Basilea Pharmaceutica released its earnings results on Feb 17, 2026. The company reported $2.434 earnings per share for the quarter, beating the consensus estimate of $2.005 by $0.43.
Is Basilea Pharmaceutica overvalued?
According to Wall Street analysts Basilea Pharmaceutica’s price is currently Overvalued.
Does Basilea Pharmaceutica pay dividends?
Basilea Pharmaceutica pays a N/A dividend of $5.38 which represents an annual dividend yield of N/A. See more information on Basilea Pharmaceutica dividends here
What is Basilea Pharmaceutica’s EPS estimate?
Basilea Pharmaceutica’s EPS estimate is 4.09.
How many shares outstanding does Basilea Pharmaceutica have?
Basilea Pharmaceutica has 13,425,260 shares outstanding.
What happened to Basilea Pharmaceutica’s price movement after its last earnings report?
Basilea Pharmaceutica reported an EPS of $2.434 in its last earnings report, beating expectations of $2.005. Following the earnings report the stock price went down -5.658%.
Which hedge fund is a major shareholder of Basilea Pharmaceutica?
Currently, no hedge funds are holding shares in BPMUF
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Basilea Pharmaceutica
Basilea Pharmaceutica AG operates as a commercial-stage biopharmaceutical enterprise, concentrating its efforts on inventing and advancing treatments to address critical unmet medical needs within the therapeutic fields of oncology and anti-infectives. Its commercialized offerings include Cresemba, an azole antifungal drug available in both intravenous and oral formulations, utilized for managing invasive aspergillosis and mucormycosis in the United States and the European Union; this drug is also advancing through Phase III clinical trials in Japan for various invasive fungal infections. The company additionally provides Zevtera, an antibiotic targeting community and hospital-acquired pneumonia, which is also undergoing Phase III clinical development for acute bacterial skin and skin structure infections, along with Staphylococcus aureus bacteremia. Beyond its current portfolio, Basilea's pipeline features Derazantinib, a small molecule inhibitor in Phase 2 clinical trials for bile duct cancer, and in Phase 1/2 trials for both bladder and stomach cancers, as well as Lisavanbulin, a novel tumor checkpoint controller drug. Established in 2000, Basilea Pharmaceutica AG maintains its corporate headquarters in Basel, Switzerland.
Ownership Overview
―
Insiders
3.57% Mutual Funds
0.11% Other Institutional Investors
85.60% Public Companies and
Individual Investors